Skip to main content

Canada The Globe and Mail’s thalidomide coverage short-listed for public service journalism award

Thalidomide victim Johanne Hebert at her home in Montreal, Quebec on November 14, 2014.

Michelle Siu/The Globe and Mail

The Globe and Mail is one of six finalists for the 2014 Michener Award for meritorious public service journalism.

Judges of the prestigious award short-listed The Globe for its series of articles about the lasting impact of the drug thalidomide, detailing how aging victims still suffered half a century later from the legacy of a long-forgotten public-health failure.

The articles prompted the federal government to offer a financial-support package.

Story continues below advertisement

"With great sensitivity, the Globe and Mail gave survivors and their families a national voice as they spoke of the growing physical, mental and financial toll," the Michener Awards Foundation said in announcing the 2014 nominations Wednesday.

The Globe's thalidomide coverage has also been nominated for a 2014 National Newspaper Award.

Other Michener finalists announced Wednesday are:

The Quebec magazine L'actualité, for an eight-month investigation into the Canadian military failure to handle complaints of sexual assault and harassment within its ranks.

The Canadian Press news agency, for highlighting the problems with the electoral reform bill, Bill C-23, which the Conservative government had dubbed the Fair Elections Act.

The Canadian Broadcasting Corporation, for its reporting on the abuses and problems related to the federal temporary foreign workers program.

CBC North, for its examination of the death of a three-month-old Inuit boy in Cape Dorset, which underscored the health-care problems in Nunavut.

Story continues below advertisement

The Vancouver Sun, for its investigation into the struggles of foster children after they turn 19 and are no longer wards of the province.

Governor-General David Johnston will announce the winner at a ceremony at Rideau Hall on June 18.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter